Invasive lobular breast cancer (ILC) is less common than invasive ductal breast cancer (IDC), more difficult to detect mammographically, and usually diagnosed at a later stage. Does delayed diagnosis of ILC affect survival? We used a national registry to compare outcomes of patients with stage-matched ILC and IDC.
Query of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) tumor registry identified 263,408 women diagnosed with IDC or ILC between 1993 and 2003. Survival of patients matched by T and N stage was compared using Kaplan-Meier curves and log-rank analysis.
When compared with IDC, ILC was more likely to be >2 cm (43.1 vs. 32.6%; P < 0.001), lymph node positive (36.8 vs. 34.4%; P < 0.001), and ER positive (93.1 vs. 75.6%; P < 0.001). The 5-year disease-specific survival (DSS) was significantly better for patients with ILC than for those with IDC, before (90 vs. 88%; P < 0.001) and after matching for stage T1N0 (98 vs. 96%; P < 0.001), T2N0 (94 vs. 88%; P < 0.001), and T3N0 (92 vs. 83%, P < 0.001). The 5-year DSS for patients with nodal metastasis of ILC vs. IDC was 89% vs. 88% (P = NS) for stage T1N1, 81 vs. 73% (P < 0.001) for T2N1, and 72 vs. 56% (P < 0.001) for T3N1. Multivariate analysis identified a 14% survival benefit for ILC (hazard ratio 0.86, 95% confidence interval 0.80–0.92).
Stage-matched prognosis is better for patients with ILC than for those with IDC. Our findings support a different biology for ILC and are important for counseling and risk stratification.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975;36:1–85.
Li CI, Anderson BO, Porter P, et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561–9.
Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 1979;3:467–88.
De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404–11.
Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 2002;4:5–8.
Le Gal M, Ollivier L, Asselain B, et al. Mammographic features of 455 invasive lobular carcinomas. Radiology. 1992;185:705–8.
Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol. 1993;161:957–60.
Arpino G, Bardou VJ, Clark GM, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.
Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8.
Molland JG, Donnellan M, Janu NC, et al. Infiltrating lobular carcinoma–a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast. 2004;13:389–96.
Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26:3006–14.
Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77:113–20.
Silverstein MJ, Lewinsky BS, Waisman JR, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73:1673–7.
Allemani C, Sant M, Berrino F, et al. Prognostic value of morphology and hormone receptor status in breast cancer—a population-based study. Br J Cancer. 2004;91:1263–8.
Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003;163:2149–53.
Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997;76:1234–40.
du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251–7.
Mhuircheartaigh JN, Curran C, Hennessy E, et al. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg. 2008;95:827–33.
Viale G, Rotmensz N, Maisonneuve P, et al. Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat. 2009;117:211–4.
Jayasinghe UW, Bilous AM, Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma? Breast J. 2007;13:479–85.
Korhonen T, Huhtala H, Holli K. A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Res Treat. 2004;85:23–9.
Mersin H, Yildirim E, Gulben K, et al. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol. 2003;29:390–5.
Ashikari R, Huvos AG, Urban JA, et al. Infiltrating lobular carcinoma of the breast. Cancer. 1973;31:110–6.
Mate TP, Carter D, Fischer DB, et al. A clinical and histopathologic analysis of the results of conservation surgery and radiation therapy in stage I and II breast carcinoma. Cancer. 1986;58:1995–2002.
Havener L. Standards for cancer registries volume III: standards for completeness, quality, analysis, and management of data. North American Association of Central Cancer Registries 2004.
Surveillance, Epidemiology, and End Results (SEER) Program. Public Use Data (1973–2005). National Cancer Institute. http://www.seer.cancer.gov. Accessed November 2008.
Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual, 6th ed. Springer, New York; 2002.
Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008; 44:73–83.
Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228–33.
Katz A, Saad ED, Porter P, et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007;8:55–62.
Wickerham DL, O’Connell MJ, Costantino JP, et al. The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. Semin Oncol. 2008;35:522–9.
Bouvet M, Ollila DW, Hunt KK, et al. Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol. 1997;4:650–4.
Santiago RJ, Harris EE, Qin L, et al. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer. 2005;103:2447–54.
Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg. 2005;242:281–9.
Work was supported by grants from the Gonda (Goldschmied) Research Laboratories of the John Wayne Cancer Institute at Saint John’s Health Center. Also supported by funding from QVC and the Fashion Footwear Association of New York Charitable Foundation (New York, NY), the Margie and Robert E. Petersen Foundation (Los Angeles, CA), Mrs. Lois Rosen (Los Angeles, CA), the Associates for Breast and Prostate Cancer Studies (Santa Monica, CA), the Family of Robert Novick (Los Angeles, CA), Ruth and Martin H. Weil Fund (Los Angeles, CA), and the Wrather Family Foundation (Los Alamos, CA).
About this article
Cite this article
Wasif, N., Maggard, M.A., Ko, C.Y. et al. Invasive Lobular vs. Ductal Breast Cancer: A Stage-Matched Comparison of Outcomes. Ann Surg Oncol 17, 1862–1869 (2010). https://doi.org/10.1245/s10434-010-0953-z
- Breast Conservation Surgery
- Male Breast Cancer
- Invasive Ductal Cancer
- Invasive Ductal Cancer
- Invasive Lobular Cancer